On February 23, 2021 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that its Chief Executive Officer, Dr. Gerrit Dispersyn, will present at the upcoming H.C. Wainwright Global Life Sciences Conference, which is being held virtually from March 9-10, 2021 (Press release, Phio Pharmaceuticals, FEB 23, 2021, View Source [SID1234575476]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the conference, a corporate presentation by Dr. Dispersyn will be made available on-demand via the H.C. Wainwright conference portal starting at 7 a.m. Eastern Time on March 9, 2021. Interested parties may also access the webcast through the "Investors – Events and Presentations" section of the Company’s website. The webcast will be archived and available on the Company’s website for 90 days.